Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 12/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | CCR1 | P32246 | 2/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.42 |
| ▸ | CCR8 | P51685 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11356632 | 0.82 | KDM4E (0.54) | KDM4EPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7952182 | 0.76 | KDM4E (0.67) | KDM4EPOLBALDH1A1TGFBR1LMNA | |
| SCHEMBL5914464 | 0.75 | KDM4E (0.46) | KDM4EPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL15835314 | 0.74 | KDM4E (0.64) | KDM4EPOLBALDH1A1TGFBR1LMNA | |
| SCHEMBL944044 | 0.74 | MKNK1 (0.41) | KDM4EPOLBALDH1A1TGFBR1HTT | |
| SCHEMBL28057386 | 0.72 | CCR1 (0.58) | KDM4EPOLBTGFBR1LMNASMN1; SMN2 | |
| SCHEMBL30636788 | 0.72 | KDM4E (0.54) | KDM4EPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7966923 | 0.72 | KDM4E (0.54) | KDM4EPOLBALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL14715801 | 0.71 | KDM4E (0.47) | KDM4EPOLBALDH1A1TGFBR1LMNA | |
| SCHEMBL30606847 | 0.71 | KDM4E (0.58) | KDM4EPOLBALDH1A1TGFBR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11590241-B2 | Nanoparticle conjugated synthetic opioid prodrugs and methods of their uses | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210205472-A1 | NANOPARTICLE CONJUGATED SYNTHETIC OPIOID PRODRUGS AND METHODS OF THEIR USES | VIRGINIA COMMONWEALTH UNIVERSITY | 2021-07-08 | — | — | US | disclosed |
| EP-3416644-A1 | NANOPARTICLE CONJUGATED SYNTHETIC OPIOID PRODRUGS AND METHODS OF THEIR USE | Virginia Commonwealth University (US) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017143126-A1 | NANOPARTICLE CONJUGATED SYNTHETIC OPIOID PRODRUGS AND METHODS OF THEIR USE | VIRGINIA COMMONWEALTH UNIVERSITY (US) | 2017-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11590241-B2 | Nanoparticle conjugated synthetic opioid prodrugs and methods of their uses | OPRM1, OPRK1, OPRL1 | KDM4E 3558/4885POLB 1041/4885ALDH1A1 568/4885 |
| US-20210205472-A1 | NANOPARTICLE CONJUGATED SYNTHETIC OPIOID PRODRUGS AND METHODS OF THEIR USES | OPRM1, OPRK1, OPRL1 | KDM4E 3558/4885POLB 1041/4885ALDH1A1 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.